Updated data showed that Roche ' s Tecentriq in combination with Avastin shrank tumours in people with unresectable or advanced hepatocellular carcinoma (HCC)
Roche will today present updated data from a Phase Ib study evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable or advanced hepatocellular carcinoma (HCC), the most common form of liver cancer.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver | Liver Cancer | Pharmaceuticals | Study | Urology & Nephrology